Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether survival can be prolonged in patients with
castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.